Lung Cancer

early stage mouth cancer :: Article Creator Number Stages And Grades Of Mouth Cancer The stage of mouth cancer tells you how big it is,  its depth, and whether it has spread. The grade tells you how much the cancer cells look like normal cells. This gives your doctor an idea of how the cancer might behave and what treatment you need.  There are different ways of staging mouth cancer. These are the number staging system and the TNM system. The Number staging system divides mouth cancer into 4 main stages, from 1 to 4. Stage 1 is an early cancer and stage 4 is an advanced cancer. Some doctors also use stage 0.  Doctors might also use the TNM staging system. Doctors stage mouth cancers differently from cancers that start in the throat behind the mouth (oropharyngeal cancer). How do doctors find out your stage? There are different ways to find out your stage. Your doctor might use: clinical staging before treatm...

stage 3 lung cancer reddit :: Article Creator A 37-year-old Nurse Got Unusually Short Of Breath On A Hike. She Had Stage 4 Lung Cancer. Lung cancer is rare in people under 45, but more women who have never smoked are developing the disease. Tiffany Job was surprised by how out of breath she felt on a hike. She was young, healthy, and never smoked so was shocked when she was diagnosed with lung cancer. Thanks for signing up! Access your favorite topics in a personalized feed while you're on the go. Download the app By clicking "Sign Up", you accept our Terms of Service and Privacy Policy. You can opt-out at any time by visiting our Preferences page or by clicking "unsubscribe" at the bottom of the email. On a hike in July 2020, Tiffany Job found herself incredibly short of breath. "I couldn't go 20 yards without my heart rate shooting up," she told The Patient Story. ...

pulmonary sarcoidosis diagnosis :: Article Creator Sarcoidosis Immune Biomarkers, Potential Targeted Treatment ID'd An immune cell called a type 1 innate lymphoid cell is found at much higher levels in skin granulomas, that is, clumps of immune cells, of people with sarcoidosis relative to those with non-sarcoid skin granulomas, according to research that shows high levels of the cells were also found in blood and lung samples of sarcoidosis patients, meaning they may be a useful diagnostic biomarker of the disease. In a mouse model of the disease, University of Pennsylvania researchers found that blocking an immune pathway called CXCR4 in the cells can prevent granulomas from forming. The study, "Recruitment of CXCR4+ type 1 lymphoid cells distinguishes sarcoidosis from other skin granulomatous disease," was published in The Journal of Clinical Investigation. The findings suggest measuring type 1 innate lymphoid cell levels may ai...

dr pulmonologist :: Article Creator Styrene Leak In Greater Cincinnati Unlikely To Have Long-term Health Effects, Says Expert CINCINNATI (WKRC) - A local lung specialist has reassured residents that short-term exposure to styrene, a compound used in plastics, is unlikely to have lingering health impacts. Hamilton County public health providers have declared the danger from the recent styrene leak in Whitewater Township to be over. Dr. Bobby Burkes, a pulmonologist at UC Health, explained the typical symptoms of acute styrene exposure. "Generally, it's associated with classic dizziness, nausea, and the general feeling of being unwell, but it can also cause coughing and burning in the chest," said Dr. Burkes. Dr. Burkes, who has extensive experience with pulmonary symptoms, shared a personal connection to a similar incident in East Palestine. "The last time this happened in the state of Ohio in East Palestine, I'm from a...

pediatric lung tumors :: Article Creator Utah Mom With Terminal Cancer Plans Her Own Funeral After Three Month Diagnosis A Utah mother with terminal cancer planned her funeral after receiving a diagnosis from doctors telling her she had three months left to live (GoFundMe) A Utah mother battling a rare terminal cancer planned her funeral after being diagnosed with three months to live. In her GoFundMe campaign, Erika Diarte-Carr, 30, revealed that she's been struggling with Stage 4 small-cell lung carcinoma for the past two years, and doctors gave her a terminal diagnosis. After an 18 September oncologist appointment, she no longer planned on pursuing treatments as she was told that they would "no longer help." The doctors told her she had at most three months left. "3 months to spend with my babies and loved ones. 3 months to make the best of what time I have left," she explained. "During these next couple of months...

sarcoma metastasis to lung treatment :: Article Creator Moleculin Announces Positive In Vivo Efficacy Data Of Annamycin In Orthotopic And Experimental Lung Metastatic Models Of Sarcoma Data recently presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer Treatment with Annamycin results in statistically significant inhibition of tumor growth and extension of survival in orthotopic lung cancer models Annamycin continues to be 100% non-cardiotoxic HOUSTON, Sept. 23, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the recent presentation of positive in vivo efficacy data of Annamycin in orthotopic and experimental lung metastatic models of sarcoma. (PRNewsfoto/Moleculin Biotech, ...

breast cancer that metastasized to lungs :: Article Creator T-DXd Shows Promise In Treating HER2+ Breast Cancer With Brain Mets Nancy Lin, MD, discusses the efficacy of T-DXd for brain metastases as seen in DESTINYBreast-12 compared with other agents. The phase 3b/4 DESTINYBreast-12 study (NCT04739761) assessed the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu) in patients with HER2+ metastatic breast cancer. Participants were divided into two groups: those with stable or active brain metastases (BM cohort) and those without BM. The primary endpoints were progression-free survival (PFS) for the BM cohort and objective response rate (ORR) for the non-BM cohort. Secondary endpoints included CNS PFS, CNS ORR, and safety. Results showed that T-DXd demonstrated significant and durable clinical activity in both groups, including intracranial activity. The BM cohort had a 12-month PFS of 61.6%, and the non-BM cohort had a 12-month...